October 31, 2007 05:06 ET

Linde Gas Therapeutics again awards highly valuable research fund

MUNCHEN, GERMANY--(Marketwire - October 31, 2007) -

- Only research fund of its kind worldwide in the field of gaseous
medicinal products
- One million US dollars research fund awarded to eight scientists

Munich, 31 October, 2007 - The Linde business unit Linde Gas Therapeutics has joined the Karolinska Institute and Harvard Medical International yesterday in awarding the "Gas Enabled Medical Innovations (GEMI) Fund" which is valued at one million US dollars. "With the GEMI Fund we want to encourage leading medical professionals and scientists to intensify research in the field of medical gases.", said Professor Dr. Wolfgang Reitzle, Chief Executive Officer of Linde AG, when awarding the grants. "These research results will empower us to develop new diagnostic and therapeutic solutions to help people all over the world."

This year's GEMI Fund research grant is shared by the following eight researchers:

- The biochemist and immunologist Prof. Dr. Ana Claudia Zenclussen (Charité - University Medical Centre, Berlin) is investigating the therapeutic potential of carbon monoxide in the prevention of spontaneous abortion.

- The neurologist and assistant professor Dr. Roland Veltkamp (University Medical Centre Heidelberg) is researching the protective effect of a special oxygen therapy in acute ischemic stroke.

- Prof. Dr. Russel Morris (UK) is studying the treatment of certain cardiovascular diseases with the help of highly porous materials that store nitric oxide.

- Prof. Dr. Miguel Soares (Portugal) is investigating the role of nitric and carbon monoxide in malaria prevention.

- Prof. Dr. Fumito Ichinose (USA) is studying the impact of hydrogen sulphide on the cardiovascular system.

- Dr. Hagir Suliman (USA) is developing a form of carbon monoxide inhalation therapy for cardioprotection.

- The biochemist and pharmacologist Dr. Sylvain Doré (USA) is studying the protective role of carbon monoxide on the nervous system after strokes.

- Prof. Dr. Joseph Szurszewski (USA) is investigating the role of hydrogen sulphide in inflammatory bowel disease.

Linde Gas Therapeutics is a leading provider of gaseous pharmaceuticals and related medical devices worldwide. One of the business objectives is research and development of innovative therapies that address the clinical use of medical gases. To this end, Linde Gas Therapeutics has provided a research fund to grant one million US dollars every two years since 2003 for the "Gas Enabled Medical Innovations (GEMI) Fund" which is awarded in co-operation with Harvard Medical International (Boston/USA) and the Karolinska Institute (Stockholm/Sweden). The GEMI Fund board, which consists of internationally renowned scientists, decides on the grantees. The Linde Group is a world-leading gases and engineering company with around 49,000 employees working in more than 70 countries worldwide. Following the acquisition of The BOC Group plc, the company has sales of around 12 billion euro per annum. The strategy of The Linde Group is geared towards earnings-based growth and focuses on the expansion of its international business with forward-looking products and services.

For more information, please see The Linde Group online at

For further information:

The Linde Group:
Uwe Wolfinger
Telephone: +49.89 3.57 57-1320

Linde Gas Therapeutics
Dr. Frank Niemann
Telephone: +49.89.370 00-274

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information